Narrow Band Imaging | MD Buyline
Learn all about the FDA cleared Narrow Band Imaging (NBI) from Olympu. Find out what is claims to do and how it promises urologists and surgeons the ability to visualize the boundaries of lesions more efficiently. MD Buyline, the leader in healthcare supply chain management solutions, has more details. View the full article at http://www.mdbuyline.com/blog/narrow-band-imaging-nbi-cost-effective-bladder-visualization/.
Published on: Mar 3, 2016
Transcripts - Narrow Band Imaging | MD Buyline
Narrow Band Imaging (NBI):
Cost-Effective Bladder Visualization
On December 14th, the FDA cleared Olympus’ Narrow Band Imaging (NBI),
for use in visualizing Non-Muscle Invasive Bladder Cancer (NMIBC). NBI
promises urologists and surgeons the ability to visualize the boundaries of
lesions more efficiently. Long believed to be able to improve the
visualization of bladder lesions, a 2012 meta-analysis found an additional
17% of patients and additional 24% of tumors were detected by NBI when
compared to white-light imaging, based on a weighted average. In another
study, NBI had significantly higher sensitivity for the visualization of bladder
tumor recurrence (100% vs. 87%) as compared to white-light imaging.
This improved visualization occurs without the need for dyes or drugs
through the use of optical filters. NBI technology utilizes only blue and green
wavelengths that are absorbed more strongly by hemoglobin in the blood.
When exposed to these wavelengths tumors and polyps appear darker than
the sounding tissue since cancerous tissue is often more highly vascularized
than healthy tissue. This allows the physician to better visualize the lesion
boundaries and remove potentially cancerous tissue as compared to
traditional methods like white-light cystoscopy.
Role in ReducingCosts
Bladder cancer currently has the highest lifetime treatment costs per
patient of all cancers and treatment costs for NMIBC were estimated to be
$157.5 million for 2009-2014 alone. These substantial costs are due to the
high rate of recurrence and disease progression that requires continuous
long-term monitoring for these patients. Some of this cost could potentially
be mitigated by NBI due to improved visualization and potential cancer
detection which could lead to earlier intervention and a reduction in both
the cost and invasiveness of treatment.
Olympus also claims that the enhanced visibility of lesion margins could lead
to more complete resection which would reduce the chances of recurrence.
Additionally, NBI can be used throughout patient management and follow-
up and requires no additional capital or consumable investment for existing
Olympus users. Company representatives have stated that the technology is
already built into existing CV-170 (office based systems) CV-190, OTVS -190,
CV-180 and OTV-7s Pro, provided they were purchased in the last 6 to 7